ACUTE REPETITIVE SEIZURES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

The soaring patient base inevitably increases the probability of acute repetitive seizures occurring among epileptic patients. As acute repetitive seizures can potentially be life-threatening if not addressed promptly with proper medication, there has been huge demand for anti-epileptic drugs and other treatment options. Several innovative drug formulations, advanced therapeutics such as neurostimulation devices and gene therapies, and efficient healthcare infrastructure are aiding efficient management of acute repetitive seizures. Increasing prevalence of epilepsy is becoming a major concern worldwide, and is one of the key factors supplementing the growth of the acute repetitive seizures market. According to the World Health Organization, around 50 million people globally suffer from epilepsy, making it one of the most common neurological disorders. This rising patient pool of epilepsy is directly fueling the need for effective management of acute repetitive seizures.

• Neurelis, Inc.
• Bausch Health Companies Inc.
• Alexza Pharmaceuticals, Inc.
• VERITON PHARMA
• UCB S.A.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Sanofi
• GSK plc
• Eisai Co., Ltd.
• H. Lundbeck A/S
• Cognizance Biomarkers, LLC
• F. Hoffmann-La Roche Ltd.
• Torrent Pharmaceuticals Ltd.
• Amneal Pharmaceuticals LLC
• Sun Pharmaceutical Industries Ltd.